Peptides homing to tumor vasculature: Imaging and therapeutics for cancer

Recent Patents on Anti-Cancer Drug Discovery

Volumn 3, Issue 3, 2008, Pages 202-208

  Liu, Zhiguo ^a   Wu, Kaichun ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Anti vascular therapy; Cancer; Diagnosis; Imaging; Peptide; Vasculature targeting

Indexed keywords

AMINO ACID DERIVATIVE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ARGINYLGLYCYLASPARTIC ACID; CADHERIN; CYTOTOXIC AGENT; DOXORUBICIN; ENDOGLIN; HIGH MOBILITY GROUP PROTEIN; HYBRID PROTEIN; INTERFERON; KALLIKREIN; MICROSOMAL AMINOPEPTIDASE; MONOCLONAL ANTIBODY LM 609; NANOPARTICLE; NUCLEOLIN; PEPTIDE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR; PROTEIN ANTIBODY; PROTEIN DERIVATIVE; PROTEIN LYP 1; PROTEINASE; PROTEOGLYCAN; QUANTUM DOT; RADIOISOTOPE; TUMOR MARKER; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR 2; VITRONECTIN RECEPTOR; WNT2 PROTEIN;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANTIGEN ANTIBODY REACTION; ANTIGEN SPECIFICITY; BREAST CANCER; CANCER CELL DESTRUCTION; CANCER DIAGNOSIS; CANCER INHIBITION; CLINICAL TRIAL; CROSS REACTION; DISEASE MARKER; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; HYPOXEMIA; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; LIGAND BINDING; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; MELANOMA; MOLECULAR IMAGING; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PANCREAS ISLET CELL CARCINOMA; PATENT; PHAGE DISPLAY; PHENOTYPE; PRECANCER; PRIORITY JOURNAL; PROSTATE TUMOR; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN ISOLATION; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; REVIEW; SKIN TUMOR; TARGET CELL DESTRUCTION; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PATENTS AS TOPIC; PEPTIDES;

EID: 58049202265     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489208786242250     Document Type: Review

References (78)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
2. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390: 404-407.
3. Nowell PC. The clonal evolution of tumor cell populations. Science 1976; 194: 23-28.
4. Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Cell 2005; 7: 513-520.
5. Bicknell R. Vascular targeting and the inhibition of angiogenesis. Ann Oncol 1994; 5 9(S4): 45-50.
6. Ruoslahti E. Specialization of tumour vasculature. Nat Rev Cancer 2002; 2: 83-90.
7. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-257.
8. Pasqualini R, Arap W, McDonald DM. Probing the structural and molecular diversity of tumor vasculature. Trends Mol Med 2002; 8: 563-571.
9. Gee MS, Procopio WN, Makonnen S, Feldman MD, Yeilding NM, Lee WM. Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy. Am J Pathol 2003; 162: 183-193.
10. Hashizume H, Baluk P, Morikawa S, et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 2000; 156: 1363-1380.
11. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-364.
12. Enback J, Laakkonen P. Tumour-homing peptides: tools for targeting, imaging and destruction. Biochem Soc Trans 2007; 35: 780-783.
13. Christian S, Pilch J, Akerman ME, Porkka K, Laakkonen P, Ruoslahti E. Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J Cell Biol 2003; 163: 871-878.
14. Porkka K, Laakkonen P, Hoffman JA, Bernasconi M, Ruoslahti E. A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo. Proc Natl Acad Sci USA 2002; 99: 7444-7449.
15. Pasqualini R, Koivunen E, Kain R, et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 2000; 60: 722-727.
16. Pasqualini R, Koivunen E, Ruoslahti E. Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol 1997; 15: 542-546.
17. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004; 10: 415-427.
18. Mutuberria R, Satijn S, Huijbers A, et al. Isolation of human antibodies to tumor-associated endothelial cell markers by in vitro human endothelial cell selection with phage display libraries. J Immunol Methods 2004; 287: 31-47.
19. Posey JA, Khazaeli MB, DelGrosso A, et al. A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer. Cancer Biother Radiopharm 2001; 16: 125-132.
20. Molema G, de Leij LF, Meijer DK. Tumor vascular endothelium: barrier or target in tumor directed drug delivery and immunotherapy. Pharm Res 1997; 14: 2-10.
21. Jain RK. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin Oncol 2002; 29: 3-9.
22. Shockley TR, Lin K, Nagy JA, Tompkins RG, Dvorak HF, Yarmush ML. Penetration of tumor tissue by antibodies and other immunoproteins. Ann N Y Acad Sci 1991; 618: 367-382.
23. Dvorak HF, Nagy JA, Dvorak AM. Structure of solid tumors and their vasculature: Implications for therapy with monoclonal antibodies. Cancer Cells 1991; 3: 77-85.
24. Santimaria M, Moscatelli G, Viale GL, et al. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res 2003; 9: 571-579.
25. Dienst A, Grunow A, Unruh M, et al. Specific occlusion of murine and human tumor vasculature by VCAM-1-targeted recombinant fusion proteins. J Natl Cancer Inst 2005; 97: 733-747.
26. Castellani P, Borsi L, Carnemolla B, et al. Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin. Am J Pathol 2002; 161: 1695-1700.
27. Arap W, Pasqualini R, Ruoslahti E. Chemotherapy targeted to tumor vasculature. Curr Opin Oncol 1998; 10: 560-565.
28. Laakkonen P, Akerman ME, Biliran H, et al. Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Proc Natl Acad Sci USA 2004; 101: 9381-9386.
29. Liang S, Lin T, Ding J, Pan Y, et al. Screening and identification of vascular-endothelial-cell-specific binding peptide in gastric cancer. J Mol Med 2006; 84: 764-773.
30. Ellerby HM, Arap W, Ellerby LM, et al. Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 1999; 5: 1032-1038.
31. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998; 279: 377-380.
32. Curnis F, Gasparri A, Sacchi A, Cattaneo A, Magni F, Corti A. Targeted delivery of IFNgamma to tumor vessels uncouples antitumor from counterregulatory mechanisms. Cancer Res 2005; 65: 2906-2913.
33. Laakkonen P, Porkka K, Hoffman JA, Ruoslahti E. A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat Med 2002; 8: 751-755.
34. Akerman ME, Chan WC, Laakkonen P, Bhatia SN, Ruoslahti E. Nanocrystal targeting in vivo. Proc Natl Acad Sci USA 2002; 99: 12617-12621.
35. Corti A, Ponzoni M. Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs. Ann N Y Acad Sci 2004; 1028: 104-112.
36. Sacchi A, Gasparri A, Curnis F, Bellone M, Corti A. Crucial role for interferon gamma in the synergism between tumor vasculature-targeted tumor necrosis factor alpha (NGR-TNF) and doxorubicin. Cancer Res 2004; 64: 7150-7155.
37. Hajitou A, Pasqualini R, Arap W. Vascular targeting: recent advances and therapeutic perspectives. Trends Cardiovasc Med 2006; 16: 80-88.
38. Liu Y, Deisseroth A. Tumor vascular targeting therapy with viral vectors. Blood 2006; 107: 3027-3033.
39. Dickerson, E.B., Helfand, S.C.: US20030077818A1 (2003).
40. Corti, A., Curnis, F.: WO06067633A2 (2006).
41. Arap, W., Pasqualini, R.: US20050003466A1 (2005).
42. Ruoslahti, E., Essler, M.: WO02099379A2 (2002).
43. Koivunen, E., Sorsa, T., Salo, T.: WO047550A1 (1999).
44. Arap, W., Kolonin, M.G., Mintz, P.J., Pasqualini, R., Zurita, A.J.: WO04020999A1(2004).
45. Arap, W., Pasqualini, R.: WO02020722A2 (2002).
46. Sean, S.M.: WO04113497A2 (2004).
47. Oku, N., Ogino, K., Ishikawa, D., Taki, T., Tanaka, M.: EP1783140A3 ( 2007).
48. Oku, N., Ogino, K., Ishikawa, D., Tanaka, M., Taki, T.: US20046753310 and EP1122262A4 (2004).
49. Ruoslahti, E., Porkka, K., Christian, S.: US20040186056A1 (2004).
50. Ruoslahti, E., Porkka, K., Christian, S.: WO03087124A2 (2003).
51. Laakkonen, P., Porkka, K., Hoffman, J.A., Ruoslahti, E.: US20077192921 and US20070149444 (2007).
52. Laakkonen, P., Porkka, K., Hoffman, J.A., Ruoslahti, E.: US20040087499A1 (2004).
53. Laakkonen, P., Porkka, K., Hoffman, J.A., Ruoslahti, E.: EP1581790A2 ( 2005).
54. Laakkonen, P., Porkka, K., Hoffman, J.A., Ruoslahti, E.: WO03040693A2 (2003).
55. Hoffman JA, Giraudo E, Singh M, et al. Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. Cancer Cell 2003; 4: 383-391.
56. Hannahan, D., Ruoslahti, E.: WO05039495A2 (2005).
57. Hannahan, D., Ruoslahti, E.: US20060002854A1 (2006).
58. Joyce JA, Laakkonen P, Bernasconi M, Bergers G, Ruoslahti E, Hanahan D. Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 2003; 4: 393-403.
59. Hanahan, D., Ruoslahti, E., Joyce, J.A., Laakkonen, P.: US20050245445 (2005) and WO05041882A2 (2005).
60. Hallmann R, Mayer DN, Berg EL, Broermann R, Butcher EC. Novel mouse endothelial cell surface marker is suppressed during differentiation of the blood brain barrier. Dev Dyn 1995; 202: 325-332.
61. Schlingemann RO, Rietveld FJ, de Waal RM, Ferrone S, Ruiter DJ. Expression of the high molecular weight melanoma-associated antigen by pericytes during angiogenesis in tumors and in healing wounds. Am J Pathol 1990; 136: 1393-1405.
62. Arap W, Haedicke W, Bernasconi M, et al. Targeting the prostate for destruction through a vascular address. Proc Natl Acad Sci USA 2002; 99: 1527-1531.
63. Ellerby, H.M., Bredesen, D.E., Pasqualini, R., Ruoslahti, E.: WO00042973A2 (2000) and EP1150701A4 (2000).
64. Real FX, Houghton AN, Albino AP, et al. Surface antigens of melanomas and melanocytes defined by mouse monoclonal anti-bodies: specificity analysis and comparison of antigen expression in cultured cells and tissues. Cancer Res 1985; 45: 4401-4411.
65. Burg MA, Pasqualini R, Arap W, Ruoslahti E, Stallcup WB. NG2 proteoglycan-binding peptides target tumor neovasculature. Cancer Res 1999; 59: 2869-2874.
66. Burg, M.A., Pasqualini, R., Arap, W., Ruoslahti, E., Stallcup, W.B.: US20036528481B1 (2003).
67. Burg, M.A., Pasqualini, R., Arap, W., Ruoslahti, E., Stallcup, W.B.: WO00048464A1(2000) and EP1161149A4(2000).
68. Ruoslahti, E., Pasqualini, R.: WO010507A1(1997).
69. Ruoslahti, E., Essler, M., Brown, D.M.: US20050048063A1 (2005).
70. Zhi M, Wu KC, Dong L, et al. Characterization of a specific phage-displayed Peptide binding to vasculature of human gastric cancer. Cancer Biol Ther 2004; 3: 1232-1235.
71. Wu, K.C., Zhi, M., Dong, L., Hao, Z.M., Qiao, T.D., Ding, J., Fan, D.M.: CN1580075(2005).
72. Wu, K.C., Zhang, Y.Q., Cao, S.S., Zhi, M., Yan, Z., Wan, Y., Ding, J., Fan, D.M.: CN1872880(2006).
73. Liang, S.H., Ding, J., Lin, T., Pan, Y.L., Wu, K.C., Fan, D.M.: CN1709905 (2005).
74. Parker AL, Fisher KD, Oupicky D, et al. Enhanced gene transfer activity of peptide-targeted gene-delivery vectors. J Drug Target 2005; 13: 39-51.
75. Kelly KA, Allport JR, Tsourkas A, Shinde-Patil VR, Josephson L, Weissleder R. Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle. Circ Res 2005; 96: 327-336.
76. Halin C, Rondini S, Nilsson F, et al. Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat Biotechnol 2002; 20: 264-269.
77. Mukhopadhyay S, Barnes CM, Haskel A, Short SM, Barnes KR, Lippard SJ. Conjugated platinum(IV)-peptide complexes for targeting angiogenic tumor vasculature. Bioconjug Chem 2008; 19: 39-49.
78. Aird WC, Edelberg JM, Weiler-Guettler H, Simmons WW, Smith TW, Rosenberg RD. Vascular bed-specific expression of an endothelial cell gene is programmed by the tissue microenvironment. J Cell Biol 1997; 138: 1117-1124.